Literature DB >> 7916191

Familial Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles.

B Ghetti1, F Tagliavini, G Giaccone, O Bugiani, B Frangione, M R Farlow, S R Dlouhy.   

Abstract

Patients affected with Gerstmann-Sträussler-Scheinker disease from two families, one from Indiana and one of Swedish origin, have been studied. The patients are clinically characterized by cerebellar ataxia, extrapyramidal signs, and dementia. Accumulation of amyloid deposits and neurofibrillary tangles are the most conspicuous neuropathologic features. In the patients from the Indiana family, the amyloid contains an 11-kDa peptide, an amyloidogenic degradation product of the prion protein. The neurofibrillary tangles are composed of paired helical filaments and immunoreact with antibody to A68, an abnormally phosphorylated form of the microtubule-associated protein tau. In these families, the disease is caused by a point mutation in the PRNP gene. In the Indiana family, the mutation is at codon 198, and in the Swedish family at codon 217.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916191     DOI: 10.1007/BF02778006

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  21 in total

Review 1.  Inherited human prion diseases.

Authors:  K Hsiao; S B Prusiner
Journal:  Neurology       Date:  1990-12       Impact factor: 9.910

2.  Gerstmann-Sträussler-Scheinker disease. I. Extending the clinical spectrum.

Authors:  M R Farlow; R D Yee; S R Dlouhy; P M Conneally; B Azzarelli; B Ghetti
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

3.  Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome.

Authors:  D Goldgaber; L G Goldfarb; P Brown; D M Asher; W T Brown; S Lin; J W Teener; S M Feinstone; R Rubenstein; R J Kascsak
Journal:  Exp Neurol       Date:  1989-11       Impact factor: 5.330

4.  Clinical and molecular genetic study of a large German kindred with Gerstmann-Sträussler-Scheinker syndrome.

Authors:  P Brown; L G Goldfarb; W T Brown; D Goldgaber; R Rubenstein; R J Kascsak; D C Guiroy; P Piccardo; J W Boellaard; D C Gajdusek
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

5.  Identification of a protein that purifies with the scrapie prion.

Authors:  D C Bolton; M P McKinley; S B Prusiner
Journal:  Science       Date:  1982-12-24       Impact factor: 47.728

6.  Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome.

Authors:  K Hsiao; H F Baker; T J Crow; M Poulter; F Owen; J D Terwilliger; D Westaway; J Ott; S B Prusiner
Journal:  Nature       Date:  1989-03-23       Impact factor: 49.962

7.  Beta PP participates in PrP-amyloid plaques of Gerstmann-Sträussler-Scheinker disease, Indiana kindred.

Authors:  O Bugiani; G Giaccone; L Verga; B Pollo; B Frangione; M R Farlow; F Tagliavini; B Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

8.  Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies.

Authors:  C L Masters; D C Gajdusek; C J Gibbs
Journal:  Brain       Date:  1981-09       Impact factor: 13.501

9.  Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene.

Authors:  S R Dlouhy; K Hsiao; M R Farlow; T Foroud; P M Conneally; P Johnson; S B Prusiner; M E Hodes; B Ghetti
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

10.  Amyloid protein of Gerstmann-Sträussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58.

Authors:  F Tagliavini; F Prelli; J Ghiso; O Bugiani; D Serban; S B Prusiner; M R Farlow; B Ghetti; B Frangione
Journal:  EMBO J       Date:  1991-03       Impact factor: 11.598

View more
  17 in total

1.  Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.

Authors:  Suman Jayadev; David Nochlin; Parvoneh Poorkaj; Ellen J Steinbart; James A Mastrianni; Thomas J Montine; Bernardino Ghetti; Gerard D Schellenberg; Thomas D Bird; James B Leverenz
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

2.  Molecular morphology and toxicity of cytoplasmic prion protein aggregates in neuronal and non-neuronal cells.

Authors:  Catherine Grenier; Cyntia Bissonnette; Leonid Volkov; Xavier Roucou
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

Review 3.  Immunomodulation for prion and prion-related diseases.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

Review 4.  Frontotemporal dementia: implications for understanding Alzheimer disease.

Authors:  Michel Goedert; Bernardino Ghetti; Maria Grazia Spillantini
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 5.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

6.  Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G)

Authors:  R Vidal; F Garzuly; H Budka; M Lalowski; R P Linke; F Brittig; B Frangione; T Wisniewski
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

7.  Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP.

Authors:  B Ghetti; P Piccardo; M G Spillantini; Y Ichimiya; M Porro; F Perini; T Kitamoto; J Tateishi; C Seiler; B Frangione; O Bugiani; G Giaccone; F Prelli; M Goedert; S R Dlouhy; F Tagliavini
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

Review 8.  Tau, prions and Aβ: the triad of neurodegeneration.

Authors:  Lilla Reiniger; Ana Lukic; Jacqueline Linehan; Peter Rudge; John Collinge; Simon Mead; Sebastian Brandner
Journal:  Acta Neuropathol       Date:  2010-05-16       Impact factor: 17.088

9.  Translation of the prion protein mRNA is robust in astrocytes but does not amplify during reactive astrocytosis in the mouse brain.

Authors:  Walker S Jackson; Clemens Krost; Andrew W Borkowski; Lech Kaczmarczyk
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

10.  Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions.

Authors:  Patricia Aguilar-Calvo; Alejandro M Sevillano; Jaidev Bapat; Katrin Soldau; Daniel R Sandoval; Hermann C Altmeppen; Luise Linsenmeier; Donald P Pizzo; Michael D Geschwind; Henry Sanchez; Brian S Appleby; Mark L Cohen; Jiri G Safar; Steven D Edland; Markus Glatzel; K Peter R Nilsson; Jeffrey D Esko; Christina J Sigurdson
Journal:  Acta Neuropathol       Date:  2019-10-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.